Pharmbio Korea Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmbio Korea Inc.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
Alvogen has signed marketing deals with local firms in Canada, Israel and South Korea for the teriparatide drug it has licensed from Pfenex. In the US, Pfenex has just completed a human factors study it feels should support a therapeutic equivalence rating for its Forteo rival.
Surgical staples underpin surgeries in every operating room in the country, and are, well, staples of the businesses of Ethicon Endo-Surgery and Covidien, which together control 95% of the US surgical staples market. But now, in colorectal, bariatric, and thoracic procedures, some of the most promising markets for surgical staples, a threat is entering from the wings. NiTi Surgical Solutions has begun selling an alternative to staples, with a platform that it calls BioDynamix Anastomosis Technology, by which it describes compression devices that adjust to an organ's diameter to promote healing that's as natural as possible.